These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 26452447

  • 1. Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
    Egan KB, Miner MM, Suh M, McVary K, Ni X, Roehrborn CG, Wittert G, Wong DG, Rosen RC.
    Andrology; 2015 Nov; 3(6):1165-72. PubMed ID: 26452447
    [Abstract] [Full Text] [Related]

  • 2. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 3. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M.
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team.
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [Abstract] [Full Text] [Related]

  • 5. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
    Chapple CR, Roehrborn CG, McVary K, Ilo D, Henneges C, Viktrup L.
    Eur Urol; 2015 Jan; 67(1):114-122. PubMed ID: 25301757
    [Abstract] [Full Text] [Related]

  • 6. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [Abstract] [Full Text] [Related]

  • 8. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
    Vlachopoulos C, Oelke M, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Büttner H.
    Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
    [Abstract] [Full Text] [Related]

  • 9. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC.
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [Abstract] [Full Text] [Related]

  • 10. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, Morisaki Y, Viktrup L.
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [Abstract] [Full Text] [Related]

  • 11. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 12. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O, Ozeki A, Suzuki N, Murakami M.
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A, Casabe A, Rodriguez Baigorri G, Cobreros C.
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS.
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [Abstract] [Full Text] [Related]

  • 15. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L.
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [Abstract] [Full Text] [Related]

  • 16. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A.
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
    Oelke M, Wagg A, Takita Y, Büttner H, Viktrup L.
    BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
    [Abstract] [Full Text] [Related]

  • 18. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [Abstract] [Full Text] [Related]

  • 19. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF, Liao CH, Kuo HC.
    Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
    [Abstract] [Full Text] [Related]

  • 20. Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.
    Angalakuditi M, Seifert RF, Hayes RP, O'Leary MP, Viktrup L.
    Health Qual Life Outcomes; 2010 Nov 12; 8():131. PubMed ID: 21073697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.